Anika Therapeutics (ANIK) AI Stock Analysis

• Market Cap: $207.09M
• Dividend Yield: N/A
• Average Volume (3M): 174.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: -31.29%
• EPS Growth: 65.68%
• Country: US
• Employees: 288
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.31
• Shares Outstanding: 14,421,219
• 10 Day Avg. Volume: 181,118
• 30 Day Avg. Volume: 174,954
• PEG Ratio: 0.16
• Price to Book (P/B): 0.96
• Price to Sales (P/S): 1.22
• P/FCF Ratio: 31.59
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: 1.54
• Enterprise Value/Gross Profit: 2.72
• Enterprise Value/Ebitda: -42.51
• 1Y Price Target: $17.50
• Price Target Upside: 79.49% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.49
• Revenue Forecast (FY): $116.35M

• Rating: 60 Neutral
• Price Target: $15.00 ▲(53.85% Upside)
• Action: Reiterated Date: 02/28/26
• Date: Action: Reiterated 02/28/26

ANIK scores 60 primarily due to improving revenue and cash-flow trends alongside a low-leverage balance sheet, supported by constructive 2026 guidance and profitability/cost-improvement actions. The score is held back by ongoing net losses and earnings volatility, stretched technical momentum (overbought signals), and regulatory/OEM-channel risks highlighted on the call.

Positive Factors

Conservative balance sheet, low leverage

Low debt and a conservative capital structure give Anika durable financial flexibility to fund regulatory work, manufacturing scale-ups, and commercial investments without forcing dilutive financing. This supports multi-quarter execution while absorbing near-term revenue volatility.

Commercial channel momentum and product adoption

Sustained double-digit commercial-channel growth and rising surgeon adoption for Integrity indicate improving market traction and durable revenue diversification away from OEM dependence, increasing repeatable procedure volumes and long-term sales runway across geographies.

Improved cash generation and liquidity

Material improvement to operating and free cash flow plus strong cash liquidity and no net debt provide a lasting cushion to fund capex, R&D and regulatory activities, while buybacks reflect confidence and improve capital returns if cash generation remains consistent.

Negative Factors

Hyalofast regulatory setback and PMA uncertainty

A Phase III shortfall and an FDA deficiency letter create structural timeline and investment uncertainty for a key pipeline product. Additional CMC/clinical requirements could delay market entry and materially compress projected 2027 revenue contribution, raising long-term execution risk.

OEM channel pricing pressure and revenue decline

Sustained OEM pricing pressure undermines a sizable revenue stream and limits margin recovery even if unit demand holds. Continued OEM weakness requires Anika to replace lost OEM volumes with higher‑margin commercial sales to stabilize long-term top-line and profit trends.

Earnings volatility and ongoing net losses

Historic swings from profit to sizable losses show structural earnings instability. Even with recent cash flow gains, persistent negative net income and inconsistent margins increase execution risk and mean sustained improvement must be proven over multiple quarters to be durable.

Anika Therapeutics Business Overview & Revenue Model

Company Description

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

How the Company Makes Money

Anika Therapeutics generates revenue primarily through the sale of its proprietary products, particularly its viscosupplement injections, which are sold to healthcare providers and distributors. The company also earns revenue from licensing agreements and collaborations with other pharmaceutical and biotechnology firms, which may involve upfront payments, milestone payments, and royalties on sales of partnered products. Additionally, Anika pursues research and development contracts that can provide funding and support for its product pipeline. Key partnerships can enhance its market reach and product offerings, contributing significantly to its earnings.

Anika Therapeutics Financial Statement Overview

Summary

Mixed fundamentals: revenue rebounded strongly in the TTM and cash flow improved to positive operating and free cash flow, supported by a conservative balance sheet. However, profitability remains weak with a net loss, negative returns on equity, and multi-year earnings inconsistency.

Income Statement

TTM (Trailing-Twelve-Months) revenue rebounded strongly (up ~39%), but profitability remains weak with a net loss and negative net margin. Gross profit is still solid, yet operating performance is pressured as results have been inconsistent over the last several years (profits in 2021 followed by sizable losses in 2022–2025), signaling limited earnings stability despite the recent top-line recovery.

Balance Sheet

Leverage is conservative with low debt relative to equity (debt-to-equity ~0.17 in TTM (Trailing-Twelve-Months)), which provides financial flexibility. However, shareholder returns are negative due to ongoing losses, and equity has trended down versus prior years, indicating that while the balance sheet is not highly levered, profitability needs to improve to rebuild capital strength.

Cash Flow

Cash generation improved meaningfully in TTM (Trailing-Twelve-Months), with positive operating cash flow and positive free cash flow, a notable turnaround from negative free cash flow in 2024 and weaker cash performance in 2023. The key risk is cash flow quality versus earnings: despite positive cash flow, net income is still negative and cash flow metrics have been volatile year-to-year, so consistency remains to be proven.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	112.82M	119.91M	120.79M	113.83M	147.79M
Gross Profit	63.81M	76.00M	82.53M	73.22M	82.94M
EBITDA	-1.83M	3.02M	15.06M	18.16M	-4.16M
Net Income	-10.88M	-56.38M	-82.67M	-14.86M	4.13M
Balance Sheet
Total Assets	190.27M	202.74M	270.63M	349.13M	347.54M
Cash, Cash Equivalents and Short-Term Investments	57.48M	55.63M	68.74M	86.33M	94.39M
Total Debt	24.20M	25.93M	27.74M	30.89M	20.95M
Total Liabilities	46.80M	48.75M	58.37M	63.56M	60.45M
Stockholders Equity	143.47M	153.99M	212.26M	285.56M	287.08M
Cash Flow
Free Cash Flow	4.36M	-2.33M	-7.21M	-3.08M	3.25M
Operating Cash Flow	11.19M	5.40M	-1.79M	4.41M	8.40M
Investing Cash Flow	-401.00K	-8.33M	-5.43M	-7.49M	-3.12M
Financing Cash Flow	-10.55M	-12.73M	-6.32M	-4.85M	-6.78M

Anika Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANIK, the sentiment is Positive. The current price of 9.75 is below the 20-day moving average (MA) of 10.68, below the 50-day MA of 9.94, and below the 200-day MA of 9.96, indicating a bullish trend. The MACD of 0.73 indicates Negative momentum. The RSI at 88.07 is Negative, neither overbought nor oversold. The STOCH value of 89.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANIK.

Anika Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FONR	66 Neutral	$116.80M	16.52	4.34%	―	3.36%	-21.15%
XTNT	66 Neutral	$79.84M	55.88	3.64%	―	16.88%	―
ANIK	60 Neutral	$207.09M	-18.92	-8.73%	―	-31.29%	65.68%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RCEL	50 Neutral	$154.08M	-2.87	―	―	20.59%	18.61%
NSPR	47 Neutral	$75.42M	-2.11	-87.61%	―	14.04%	-0.65%

Anika Therapeutics Corporate Events

Anika Announces Executive Transition Amid Stable Quarterly Results

On February 26, 2026, Anika reported fourth-quarter 2025 revenue of $30.6 million, flat year on year, with gross margin expanding to 63% as Commercial Channel sales grew 22% and OEM revenue fell 12% amid anticipated U.S. pricing pressure. For full-year 2025, revenue declined 6% to $112.8 million while gross margin reached 57%, the company generated $11.2 million in operating cash flow and $4.4 million in free cash flow, and Integrity implant revenue more than doubled to $6 million on rising surgeon adoption.

The company highlighted progress on key pipeline programs, including filing the Hyalofast PMA and receiving FDA feedback in January 2026, completing toxicity studies and initiating a bioequivalence study for Cingal ahead of an NDA submission. Anika also began actions to cut general and administrative expenses in early 2026 following strategic divestitures, targeting millions in annual adjusted EBITDA and stock-based compensation savings, reaffirmed 2026 revenue guidance with expected Commercial growth and relatively flat OEM performance, and continued a $15 million share repurchase program slated to conclude in the second quarter of 2026.

On the governance front, Anika entered into a transition agreement on February 26, 2026, with Executive Vice President, General Counsel and Corporate Secretary Mr. Colleran, who will remain in his role through May 1, 2026, with continued salary, benefits and equity vesting during the transition period. Subject to the conditions of the agreement, he will be eligible for separation pay and benefits under a prior executive retention agreement and has provided the company and its affiliates with a general release of claims, signaling a structured leadership transition for investors and employees.

The most recent analyst rating on (ANIK) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Anika Therapeutics stock, see the ANIK Stock Forecast page.

Anika Therapeutics Announces CEO Transition and Governance Changes

On January 8, 2026, Anika Therapeutics announced a planned leadership transition effective February 1, 2026, under which Stephen (Steve) Griffin, currently Executive Vice President, Chief Financial Officer and Chief Operating Officer, will become President and Chief Executive Officer and join the board, succeeding Cheryl R. Blanchard, who will move into the role of Executive Chair. Blanchard’s transition is governed by a multi-year services and separation framework that keeps her as Executive Chair for 12 months, then as Special Advisor for six months and an employee for an additional six months through January 31, 2028, with continued board service through the 2028 annual meeting, while Griffin’s new employment agreement sets his CEO compensation and a three-year vesting schedule for equity awards. The company reaffirmed its fiscal 2025 guidance and also reported governance changes including the appointment of director Jack Henneman as Lead Independent Director and the resignation of long-serving director Susan N. Vogt, whose departure allows Griffin to join the board in line with the company’s board-size limit; taken together, these moves underscore Anika’s effort to consolidate strategic, financial and operational leadership around Griffin as it pursues profitable growth in osteoarthritis pain management and regenerative solutions, while preserving continuity through Blanchard’s ongoing involvement and indemnification protections extended to all directors.

The most recent analyst rating on (ANIK) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Anika Therapeutics stock, see the ANIK Stock Forecast page.